Product Information
Registration Status: ActiveSIN12593P
FORTEO INJECTION 20mcg/80MCL is approved to be sold in Singapore with effective from 2004-09-27. It is marketed by ELI LILLY (SINGAPORE) PTE LTD, with the registration number of SIN12593P.
This product contains Teriparatide 750mcg/3ml in the form of INJECTION, SOLUTION. It is approved for SUBCUTANEOUS use.
This product is manufactured by LILLY FRANCE in FRANCE.
It is a Prescription Only Medicine that can only be obtained from a doctor or a dentist, or a pharmacist with a prescription from a Singapore-registered doctor or dentist.
Product Reference
Important Note: For generic product, the SPC/PIL provided may not be brand specific.
{{/items}} {{^items}}Description
Teriparatide (recombinant human parathyroid hormone) is a potent anabolic agent used in the treatment of osteoporosis. It is manufactured and marketed by Eli Lilly and Company.
Indication
For the treatment of osteoporosis in men and postmenopausal women who are at high risk for having a fracture. Also used to increase bone mass in men with primary or hypogonadal osteoporosis who are at high risk for fracture.
Mechanism of Action
Teriparatide is the portion of human parathyroid hormone (PTH), amino acid sequence 1 through 34 of the complete molecule which contains amino acid sequence 1 to 84. Endogenous PTH is the primary regulator of calcium and phosphate metabolism in bone and kidney. Daily injections of teriparatide stimulates new bone formation leading to increased bone mineral density.
Pharmacokinetics
- Absorption
- Bioavailability is 95% following subcutaneous injection.
- Distribution
- * 0.12 L/kg
- Metabolism
- Hepatic
- Elimination
Clearance
* 62 L/hr [Women] * 94 L/hr [Men]
Toxicity
Effects of overexposure may include headaches, dizziness, dizziness, decreased blood pressured, decreased fetal survival, leg cramps, changes in clinical chemistry including increased in blood levels of calcium, decreased serum phosphorous, and increased urinary calcium and phosphorus.
Active Ingredient/Synonyms
PTH (1-34) | PTH 1-34 | Teriparatide recombinant human | Teriparatide |
Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.